Effect of SRT2379 on Endotoxin-Induced Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-17

Study Completion Date

2011-04-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice. The objective of this study is to test if SRT2379 may be a novel compound for the treatment of inflammatory disorders in man.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

NCT01416376

Sepsis

COMPLETED PHASE1

Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.

NCT02370030

Sepsis

UNKNOWN PHASE1/PHASE2

N2O for Acute Suicidality and Depression in the ED

NCT05710887

Suicidal Ideation Major Depressive Disorder Treatment Resistant Depression

NOT_YET_RECRUITING PHASE2

Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19

NCT05697016

Respiratory Infection Virus Respiratory Failure

UNKNOWN NA

Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery

NCT04873479

Sepsis Acute Lung Injury

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.0 g SRT2379

Single dose of 1.0g of SRT2379

Group Type ACTIVE_COMPARATOR

SRT2379

Intervention Type DRUG

SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.

1.0 g Placebo

Single dose of 1.0g of placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SRT2379

SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.

Intervention Type DRUG

Placebo

Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 21 days prior to dosing.
* Male between 18 and 35 years of age inclusive, at the time of signing the informed consent
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
* Chemistry panel, including renal and liver functions tests, without any clinically relevant abnormality
* Subjects must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 7 days following the dose of study drug

Exclusion Criteria

* Subject has had a major illness in the past 3 months or any significant chronic medical illness that the investigator would deem unfavorable for enrollment including inflammatory diseases
* Subjects with a history of any type of malignancy with the exception of successfully treated basal cell cancer of the skin
* Subject has a past or current gastrointestinal disease which may influence drug absorption
* The subject has a known positive test for hepatitis C antibody, hepatitis B surface antigen or HIV
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Subject has a history, within three years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, THC) or a positive drug results at the Screening visit
* History of alcoholism and/or is drinking more than 3 drinks per day. Alcoholism is defined as an average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
* The subject has participated in a clinical trial and has received an investigational product within three months of the dosing in the current study
* Use of prescription or non-prescription drugs, and herbal and dietary supplements within 7 days unless in the opinion of the Investigator and Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
* Subject has difficultly in donating blood or accessibility of a vein in left or right arm
* Subject has donated more than 350 mL of blood in last 3 months
* Subject uses tobacco products
* Any clinically relevant abnormality noted on the 12-lead ECG as judged by the investigator or an average QTcB or QTcF \> 450 msec
* Any other issue that, in the opinion of the Principal Investigator, would could be harmful to the subject or compromise interpretation of the data
* Prior participation in a trial where the subject received IV LPS

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Amsterdam, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.